Lumexa Imaging Holdings, Inc. (LMRI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several positive indicators: the UPMC joint venture is expected to drive growth, significant EBITDA ramp in the latter half of the year, and strong MRI growth with FastScan. Despite weather impacts, there is optimistic guidance on free cash flow and EBITDA growth. The Q&A highlighted strong PET growth and positive technology initiatives. While management was vague on some metrics, the overall sentiment and strategic developments suggest a positive short-term stock price movement.
Key Financial Performance
Consolidated Revenues $253 million, an increase of 3% compared to the same period last year. The growth was driven by a combination of volume (2/3) and rate (1/3), with advanced modalities being a higher proportion of the business and modest increases in contracted rates with payers.
System-wide Revenue Growth 4% in the quarter, driven by 2/3 volume and 1/3 rate, consistent with company modeling.
Revenue Per Unit Increased due to advanced modalities being a higher proportion of the business and modest increases in contracted rates with payers.
Advanced Modality Volumes Grew 7% year-over-year, with PET growing at 23.1% and MRI growing at 8.2%. This growth was attributed to strategic focus and seasonal campaigns targeting specific specialists.
Adjusted EBITDA $51.2 million, flat compared to $51.1 million a year ago. Seasonal and weather-related volume softness impacted Q1 EBITDA by about $4 million.
Adjusted EBITDA Margin 20.3% in Q1 2026 compared to 20.8% in Q1 2025. The slight decline was due to seasonal and weather-related volume softness and increased public company costs.
Net Income $2 million in Q1 2026 compared to a net loss of $8 million in Q1 2025. The improvement was driven by lower interest payments from refinancing debt and IPO proceeds.
GAAP EPS $0.02 per share in Q1 2026 compared to a loss in the prior year period.
Adjusted EPS $0.18 per share in Q1 2026.
Operating Cash Flow $3 million in Q1 2026, a $17 million improvement over Q1 2025, largely driven by lower interest payments from refinancing debt and IPO proceeds.
Free Cash Flow Negative $2 million in Q1 2026, a $13 million improvement over Q1 2025, reflecting disciplined growth investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI-powered breast arterial calcification solution: Continued rollout with plans for expansion into new markets and strong patient uptake.
Advanced modalities (PET and MRI): PET grew 23.1% year-over-year, MRI grew 8.2% year-over-year, contributing to strong same-center growth.
Geographic footprint expansion: Opened 2 de novo centers in South Carolina and Florida, and completed 2 acquisitions in Pennsylvania and North Carolina.
Joint ventures (JVs): First acquisition in Pennsylvania under JV with UPMC; actively advancing multiple site location plans with this partner.
Efficiency gains: Rolled out FastScan integration targeting 2/3 adoption by end of 2026; leveraging virtual cockpit for remote MRI scanning to minimize downtime and extend hours.
Cost management: Reduced interest expenses by $14 million year-over-year due to IPO proceeds used to pay down debt.
Leadership appointments: Hired Kyle Lynch as Chief Growth Officer and Rikki Mondo as Chief Enterprise Operations Officer to drive growth and operational excellence.
Market positioning: Positioned as a cost-effective outpatient imaging provider with Net Promoter Scores exceeding 90, addressing imaging bottlenecks and site neutrality trends.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cybersecurity Incident: A vendor experienced a cybersecurity breach involving Lumexa data. While the company claims no material impact on business or financial results, such incidents could harm patient trust, regulatory compliance, and operational integrity.
Weather-Related Disruptions: Weather-related disruptions in Q1 impacted patient volumes at several sites, leading to a $4 million EBITDA impact. This highlights vulnerability to external environmental factors.
Seasonality and Payer Mix: Seasonal fluctuations in payer mix, with a shift towards government payers in Q1, impacted revenue predictability and financial performance.
Integration of Acquired Facilities: Acquired facilities require time to ramp up and integrate into the operating platform, including payer enrollment, which could delay expected financial contributions.
Fixed Cost Structure: The partially fixed cost structure, including staffing and facility costs, limits flexibility to adjust expenses during periods of volume softness, impacting margins.
Stock-Based Compensation Costs: Stock-based compensation increased significantly, impacting financials. While some costs will amortize by 2026, ongoing expenses remain a concern.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company expects revenue to be in the range of $1.045 billion to $1.097 billion for the full year 2026.
Adjusted EBITDA Guidance: Adjusted EBITDA is projected to be between $234 million and $242 million for the full year 2026, including approximately $7 million of public company costs.
Adjusted EPS Guidance: Adjusted EPS is expected to range between $0.71 and $0.77 per share for the full year 2026.
Growth in Advanced Modalities: Advanced modalities, including PET and MRI, are expected to continue driving growth, with PET growing at 23.1% year-over-year and MRI at 8.2% year-over-year in Q1.
De Novo Openings: The company plans to open 8 to 10 de novo imaging centers annually to fuel future growth, with 4 new centers already opened in Q1 2026.
Joint Ventures and Partnerships: The company is actively advancing multiple site location plans with partners like UPMC and Advocate Health, and is cultivating a robust pipeline of potential health system partners.
Market Trends: The company is benefiting from long-term tailwinds such as aging populations, new treatment paradigms requiring advanced imaging, rising preventative screening rates, and a shift from inpatient to outpatient care.
Efficiency and Technology Integration: Efforts to scale efficiently include the rollout of FastScan integration targeting 2/3 adoption by the end of 2026, leveraging virtual cockpit for remote MRI scanning, and advancing AI strategies to drive operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is the UPMC joint venture expected to accelerate growth through acquisitions and de novos?
A:Yes, the UPMC joint venture is expected to drive growth through acquisitions and de novos. The partnership started in August-September of last year, and they have already acquired a facility and plan to announce several de novos this year and next.
Q:What is the expected EBITDA ramp for the year and the drivers for margin progression?
A:The company expects about 55% of adjusted EBITDA to be in the second half of the year, with a steady ramp starting from a lower point in Q1. Drivers include advanced modalities, annual deductible resets, and the ramping of 15 de novos opened since late 2024.
Q:How does this year's weather impact compare to previous years, and what is the magnitude of the drag on Q1 earnings?
A:This year's weather impact was more significant than usual, with four major weather events affecting several markets. The magnitude of the drag was larger than normal, contributing to enhanced seasonality.
Q:What are the assumptions for volume recapture in the full-year guidance?
A:The company has already recaptured a significant portion of advanced volumes, which are higher-margin. Routine volumes are coming back more slowly and are expected to ramp through Q2 and Q3. The natural ramping of business and the performance of de novos will also contribute to volume recapture.
Q:What is the update on the percentage of MRI machines with FastScan software and its impact?
A:The company started the year with 51% of MRI machines equipped with FastScan and aims to reach 66-67% by year-end. Centers with FastScan are performing well, contributing to strong MRI growth of 8.2% in Q1 and an increase in advanced volume as a percentage of total volume.
Q:What is the expected CapEx and its impact on cash flow?
A:CapEx is expected to be $5-7 million per quarter, totaling mid-to-upper $20 million for the year. Some of this will be financed, resulting in no cash outflow. The company expects cash flow to be slow in the first half of the year and pick up in the second half.
Q:What is the status of the four centers announced, and are they part of the UPMC deal?
A:Two centers are single sites (one with UPMC and one with Advocate Atrium), and two are wholly owned de novos in South Carolina and Niceville, Florida. The UPMC de novos will be part of the 8-10 planned for the year.
Q:What are the drivers of accelerating free cash flow in the second half of the year?
A:Free cash flow is expected to accelerate due to the natural ramping of business, reduced working capital timing issues, and the performance of de novos and JVs.
Q:Why was unconsolidated net revenue per scan weaker than consolidated revenue per scan?
A:The unconsolidated book of business has a lower proportion of advanced modalities compared to the consolidated book, which affected the net revenue per scan. Routine volumes were slower to recover, impacting the unconsolidated metrics.
Q:What is the size and expected contribution of the two acquisitions completed in the quarter?
A:The acquisitions are typical in size and require optimization. Their contribution in 2026 is expected to be minimal, with more significant impact anticipated in 2027 and beyond.
Q:What are the updates on technology and AI initiatives?
A:The company is focused on improving core operations, back-end efficiencies, and strategic service lines. Initiatives include FastScan deployment, virtual MRI, revenue cycle bots, and clinical tools like Ferrum and RAD AI. Near-term efforts focus on productivity and efficiency, while long-term goals aim at reimbursable revenue growth.
Q:What is the impact of the $4 million transient items on Q1 EBITDA and the growth outlook?
A:The $4 million impact from enhanced seasonality and storms affected Q1 EBITDA, which was flat. Adjusting for this, EBITDA growth would have been around 8%. The company expects steady growth in EBITDA through the year, with Q2 contributing 23.5% of annual EBITDA.
Q:What were the trends in payer mix and PET growth in Q1?
A:Payer mix dynamics were consistent with normal seasonality, with no significant changes. PET growth was 23% year-over-year in Q1, driven by new machines, marketing strategies, and additional sites.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the magnitude of Q4 seasonal lift and margin progression, as well as the exact impact of weather-related events on same-store revenue and decremental margin. Additionally, they did not provide precise metrics for the unconsolidated net revenue per scan or detailed financial contributions of the two acquisitions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI breast
Carolina
Health
JV partnership
MRI
New
UPMC
access
acquisition
approach
care
center
conversation
de novo
development
expansion
experience
focus
footprint
goal
health system
imaging
industry
integration
leader
line
location
market
mix
modality
moment
novos
opening
opportunity
outpatient
patient
plan
priority
program
service
shift
site
LMRI Transcript
Lumexa Imaging Holdings, Inc. (LMRI) Q1 2026 Earnings Call Transcript
Positive5-13
The earnings call reveals several positive indicators: the UPMC joint venture is expected to drive growth, significant EBITDA ramp in the latter half of the year, and strong MRI growth with FastScan. Despite weather impacts, there is optimistic guidance on free cash flow and EBITDA growth. The Q&A highlighted strong PET growth and positive technology initiatives. While management was vague on some metrics, the overall sentiment and strategic developments suggest a positive short-term stock price movement.
Lumexa Imaging Holdings, Inc. (LMRI) Q4 2025 Earnings Call Transcript
Positive4-2
The earnings call highlights strong financial performance with an 8% revenue increase and improved operating margins. Net income and free cash flow also rose, indicating effective cost management and operational efficiency. Despite the absence of strategic updates or risk assessments, the financial results are robust enough to predict a positive stock price movement in the short term.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
